(MENAFN Editorial) DUBLIN, Jan. 2, 2018 /PRNewswire/ --

The report has been added to Research and Markets' offering.

The Global Market for Cancer Stem Cells Will Grow from $745 Million in 2017 to $1.9 Billion by 2022 with a Compound Annual Growth Rate of 21.2% for the Period of 2017-2022

This research report presents an in-depth analysis of the global cancer stem cells market by cancer type and geographic markets.

The report includes key inhibitors that affect various factors that help in growth of cancer stem cells. The report discusses the role of supply chain members from manufacturers to researchers. The report has an in-depth analysis of key companies operating in the global cancer stem cells market. In-depth patent analysis in the report will focus on providing extensive technological trends across years and geographies such as the U.S., Europe, and China.

The cancer stem cells market is mainly segmented into two major components: cancer type and geography. Based on cancer type, the market is segmented into lung cancer, breast cancer, colorectal cancer, leukemia, melanoma, prostate cancer, brain cancer, bone cancer, and other types of cancer. The market is segmented by geography into the North America, Europe, Asia-Pacific, and ROW.

Report Includes:

27 data tables and 25 additional tables

An overview of the global market for cancer stem cells and related technologies

Analyses of global market trends, with data from 2016, estimates for 2017, and projections of compound annual growth rates (CAGRs) through 2022

Segmentation of the market by type and by region

Discussion of market dynamics, including drivers, restraints, and opportunities

Insight into the competitive landscape, including strategies, acquisitions, agreements, and new product launches

Profiles of suppliers of cancer stem cells and analyses based on market share, cancer type, and region

Key Topics Covered:

Chapter 1 Introduction
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials

Chapter 2 Summary and Highlights

Chapter 3 Market and Technology Background
Definitions
Enzymes
Coenzymes
Cofactor
Active Site
Substrate
Enzyme Inhibitors
Enzymes
Enzyme Specificity
Factors Affecting Enzymatic Action
Classification of Enzymes
Enzymes in the Human Body
Enzyme Inhibitors
Uses of Enzyme Inhibitors
Mechanism of Enzyme Inhibitors
Types of Enzyme Inhibitors
Classification of Enzyme Inhibitors
Market Segments
Proton Pump Inhibitors
Protease Inhibitors
Reverse Transcriptase Inhibitors
Kinase Inhibitors
Statins
Aromatase Inhibitors
Phosphodiesterase Type 4 Inhibitors
Phosphodiesterase Type 5 Inhibitors
Neuraminidase Inhibitors
Angiotensin-Converting Enzyme Inhibitors
Poly(ADP-ribose) Polymerase Inhibitors
Xanthine oxidase inhibitors
COX-2 Inhibitors
5-Alpha Reductase Inhibitors
Dipeptidyl Peptidase-4 Inhibitors or Gliptins
Sodium-Glucose Co-Transporter-2 Inhibitors or Gliflozins
Integrase Inhibitors
Monoamine oxidase inhibitors (MOAIs)
Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors
Acetylcholinesterase inhibitors
Aldose Reductase Inhibitors

Chapter 4 Market Breakdown by Technology Type and Region
Market by Type
Market Revenue
Market Share of Enzyme Inhibitors by Type
Market by Region
Market Overview
Market Revenue
Market Share
Proton Pump Inhibitors
Protease Inhibitors
Reverse Transcriptase Inhibitors
Kinase Inhibitors
Statins
Aromatase Inhibitors
Phosphodiesterase Type 5 Inhibitors
Neuraminidase Inhibitors
Angiotensin-Converting Enzyme Inhibitors
Poly(ADP-Ribose) Polymerase Inhibitors
Xanthine Oxidase Inhibitors
Phosphodiesterase 4 Inhibitors
Cyclooxygenase Inhibitors
5-Alpha Reductase Inhibitors
Dipeptidyl Peptidase-4 Inhibitors
Sodium-Glucose Co-Transporter-2 Inhibitors
Integrase Inhibitors
Monoamine Oxidase Inhibitors
Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors
Acetylcholinesterase Inhibitors

Chapter 5 Market Breakdown by Application
Global Market Share of Enzyme Inhibitors by Application
Cardiovascular Disease
Gastrointestinal Disorders
Acquired Immunodeficiency Syndrome
Hepatitis
Cancer
Men's Health-Erectile Dysfunction/Benign Prostatic Hyperplasia/Alopecia
Diabetes
Others

Chapter 6 Industry Structure
Proton Pump Inhibitors
Protease Inhibitors
Reverse Transcriptase Inhibitors
Kinase Inhibitors
Statins
Aromatase Inhibitors
Phosphodiesterase Type 5 Inhibitors
Neuraminidase Inhibitors
Angiotensin-Converting Enzyme Inhibitors
Poly(ADP-Ribose) Polymerase Inhibitors
Xanthine Oxidase Inhibitors
Phosphodiesterase Type 4 Inhibitors
Cyclooxygenase Inhibitors
5-Alpha Reductase Inhibitors
Dipeptidyl Peptidase-4 Inhibitors
Sodium-Glucose Co-Transporter-2 Inhibitors
Integrase Inhibitors
Monoamine Oxidase Inhibitors
Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors
Acetylcholinesterase Inhibitors

Chapter 7 Patent Review/ New Developments
Patents
Patents by Year
Patents by Type
Patents by Company
Patents by Country
Patents by Assignee
New Product Developments
New Drug Approvals for Enzyme Inhibitors
Pipeline Products for Enzyme Inhibitors
Mergers and Acquisitions

Chapter 8 Analysis of Market Opportunities
Drivers of Enzyme Inhibitors Market
Increasing Aging Population
Increasing Incidence of Diseases
Rise in Healthcare Spending
Direct-to-Consumer Advertising
New/Pipeline Products
New Indications
Mergers and Alliances
Restraints of Enzyme Inhibitors Market
Patent Expirations
Government Regulations
Price Checks
Opportunities for Enzyme Inhibitors Market
Emerging Markets
Favorable Government Policies
Research and Development
Innovation
Prescription to Over-the-Counter Switch
Challenges for Enzyme Inhibitors Market
Changing Regulatory Landscape/Market Fluctuations
Uncertainties in Drug Development
Quality Control
Patent Litigation

Chapter 9 Company Profiles

Chapter 10 Appendix: Abbreviations

Companies Mentioned

Abbott Laboratories

Abbvie Inc.

Amgen Inc.

Astrazeneca Plc

Bayer Ag

Boehringer Ingelheim International Gmbh

Bristol-Myers Squibb

Cipla Usa Inc.

Clovis Oncology

Daiichi-Sankyo Co. Ltd

Dr. Reddy's Laboratories Ltd.

Eisai Inc.

Eli Lilly And Co.

F. Hoffmann-La Roche Ag

Gilead Sciences Inc.

Glaxosmithkline Plc

Glenmark Pharmaceuticals Limited

Incyte Corp.

Janssen Global Services Llc

Kowa Pharmaceuticals America Inc.

Lupin Pharmaceuticals Inc.

Merck & Co. Inc.

Merck Kgaa

Novartis Holding Ag

Pfizer Inc.

Sanofi Genzyme Corp.

Servier

Sun Pharmaceutical Industries Ltd.

Takeda Pharmaceuticals Co.

Teva Pharmaceutical Industries Ltd.

Valeant Pharmaceuticals International Inc.

Viiv Healthcare

Vivus Inc.

Zydus Cadila

For more information about this report visit

Media Contact:

Research and Markets
Laura Wood, Senior Manager


For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:

SOURCE Research and Markets

MENAFN0201201800701241ID1096299584